In this video

Share

Gilead's Remdesivir treatment could see recurring revenue even if a Covid-19 vaccine is found: Jefferies

Jefferies' Michael Yee explains his $97 price target for Gilead Sciences, noting the drugmaker is not a "one-time pandemic stock" considering its expanding portfolio.
02:23
Fri, Jul 31 20202:14 AM EDT